Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA.
Data Tecnica International, Glen Echo, Maryland, USA.
Mov Disord. 2019 Dec;34(12):1839-1850. doi: 10.1002/mds.27845. Epub 2019 Sep 10.
Several reports have identified different patterns of Parkinson's disease progression in individuals carrying missense variants in GBA or LRRK2 genes. The overall contribution of genetic factors to the severity and progression of Parkinson's disease, however, has not been well studied.
To test the association between genetic variants and the clinical features of Parkinson's disease on a genomewide scale.
We accumulated individual data from 12 longitudinal cohorts in a total of 4093 patients with 22,307 observations for a median of 3.81 years. Genomewide associations were evaluated for 25 cross-sectional and longitudinal phenotypes. Specific variants of interest, including 90 recently identified disease-risk variants, were also investigated post hoc for candidate associations with these phenotypes.
Two variants were genomewide significant. Rs382940(T>A), within the intron of SLC44A1, was associated with reaching Hoehn and Yahr stage 3 or higher faster (hazard ratio 2.04 [1.58-2.62]; P value = 3.46E-8). Rs61863020(G>A), an intergenic variant and expression quantitative trait loci for α-2A adrenergic receptor, was associated with a lower prevalence of insomnia at baseline (odds ratio 0.63 [0.52-0.75]; P value = 4.74E-8). In the targeted analysis, we found 9 associations between known Parkinson's risk variants and more severe motor/cognitive symptoms. Also, we replicated previous reports of GBA coding variants (rs2230288: p.E365K; rs75548401: p.T408M) being associated with greater motor and cognitive decline over time, and an APOE E4 tagging variant (rs429358) being associated with greater cognitive deficits in patients.
We identified novel genetic factors associated with heterogeneity of Parkinson's disease. The results can be used for validation or hypothesis tests regarding Parkinson's disease. © 2019 International Parkinson and Movement Disorder Society.
几项报告已经确定了携带 GBA 或 LRRK2 基因突变的个体中帕金森病进展的不同模式。然而,遗传因素对帕金森病的严重程度和进展的总体贡献尚未得到很好的研究。
在全基因组范围内测试遗传变异与帕金森病临床特征之间的关联。
我们在总共 4093 名患者的 12 个纵向队列中积累了个体数据,这些患者的观察时间中位数为 3.81 年,共有 22307 次观察。对 25 个横断面和纵向表型进行了全基因组关联评估。还对特定的候选变异,包括最近确定的 90 种疾病风险变异,进行了候选关联的事后分析。
有两个变体具有全基因组意义。位于 SLC44A1 内含子内的 Rs382940(T>A)与更快达到 Hoehn 和 Yahr 阶段 3 或更高阶段相关(危险比 2.04 [1.58-2.62];P 值=3.46E-8)。Rs61863020(G>A),一个位于基因间的变体和α-2A 肾上腺素能受体的表达数量性状基因座,与基线时失眠的患病率较低相关(优势比 0.63 [0.52-0.75];P 值=4.74E-8)。在靶向分析中,我们发现了 9 个已知帕金森病风险变异与更严重的运动/认知症状之间的关联。此外,我们还复制了以前关于 GBA 编码变异(rs2230288:p.E365K;rs75548401:p.T408M)随时间推移与更大的运动和认知衰退相关,以及 APOE E4 标记变体(rs429358)与患者认知缺陷更大相关的报告。
我们发现了与帕金森病异质性相关的新的遗传因素。这些结果可用于验证或假设检验帕金森病。© 2019 国际帕金森病和运动障碍学会。